Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does
The article highlights Axsome Therapeutics (AXSM) and Moderna (MRNA) as stocks expected to perform despite macro and geopolitical risks. For AXSM, Q1 revenue rose 57% to $191.2M, but operating loss widened to $63.4M. It cites FDA acceptance for AXS-12, with potential approval by May 2027. For MRNA, it notes FDA panel support for mFLUSIVA and Q2 revenue of $145M, up 2% YoY.
How this was made
The 30-second read
Why it matters
For AXSM, the key incremental item is FDA acceptance of an AXS-12 application for narcolepsy cataplexy with a stated potential approval timeframe. For MRNA, the key incremental item is unanimous FDA panel support for mFLUSIVA, framed as likely approval and a growth catalyst after weaker COVID vaccine sales.
Market read
This is primarily a promotional, long-term thesis article. It includes specific regulatory milestones for AXSM and MRNA, but it does not introduce a new earnings print, FDA decision, or other immediate tradable event beyond what is already described.
What to watch
The article highlights revenue growth and pipeline optionality but does not quantify probability-weighted success, cash burn trajectory, or competitive dynamics for Auvelity/Sunosi/Symbravo and mFLUSIVA.
Background
The piece argues that macro and geopolitical headwinds may eventually pressure equities, so investors should favor companies expected to perform through cycles, highlighting AXSM and MRNA.
Ticker impact
Axsome says the FDA accepted its AXS-12 application for cataplexy in narcolepsy, with a potential approval window by May 2027.
Moderate upside bias on any follow-on FDA/clinical updates; near-term trading likely tied to biotech risk sentiment rather than immediate earnings.
The article provides a specific regulatory milestone (application accepted) and a timeline (May 2027), but it is still not an approval or new financial print beyond Q1 figures already referenced.
Moderna’s mFLUSIVA received unanimous FDA panel support, implying approval is likely and positioning the vaccine as a new growth driver.
Potential positive drift into FDA decision milestones; volatility likely around any FDA request or label scope changes.
The text cites a concrete regulatory review outcome (unanimous panel) and links it to commercialization and financial improvement, but it does not provide a new FDA decision date or fresh trial datapoint.
Market effects
Reinforces risk-on sentiment for late-stage biotech and vaccine platforms, but offers no new sector-wide regulatory or funding development.
Limited, as the catalysts are company-specific FDA review milestones.
Low; the article focuses on US FDA processes and company pipelines.
Counterpoint
Regulatory acceptance and panel support do not guarantee approval; label scope, safety signals, or manufacturing issues can still derail timelines and valuation assumptions.
Key entities
- companyAxsome Therapeutics
Biotech with approved products and a late-stage pipeline; FDA accepted AXS-12 application for narcolepsy cataplexy.
- companyModerna
mRNA vaccine developer; FDA panel unanimously supported mFLUSIVA, positioning it for likely approval.
- regulatorU.S. Food and Drug Administration (FDA)
Regulatory body reviewing AXS-12 and convening an expert panel for mFLUSIVA.
